A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action.
By inhibiting a certain protein, the researchers were able to reduce the signals that trigger an inflammation. The study is published in Science and was done in collaboration with the University of Texas Medical Branch, Uppsala University and Stockholm University.
“We’ve developed a new drug molecule that inhibits inflammation,” says Professor Thomas Helleday, at the Department of Oncology-Pathology, Karolinska Institutet, Sweden, who co-led the study with Dr Torkild Visnes and Dr Armando Cázares-Körner. “It acts on a protein that we believe is a general mechanism for how inflammation arises in cells.”
The discovery is the result of many years of research by Thomas Helleday’s group on how DNA is repaired by the body. One of the objectives has been to fight cancer by targeting damage to the tumour cells’ DNA. Several breakthroughs have already been reported, which have led, amongst other things, to a new treatment for congenital breast and ovarian cancer using so-called PARP inhibitors, which has been available for some years.
Trials on mice
It was when developing a new molecule for inhibiting the enzyme that repairs oxygen damage to DNA that the researchers found, to their surprise, that it also dampened inflammation. It turned out that the enzyme OGG1, apart from repairing DNA, also triggers inflammation.
The inhibitor blocks the release of inflammatory proteins, such as TNF alpha. In trials on mice with acute pulmonary disease, the researchers succeeded in dampening the inflammation.
“This discovery could give rise to a new treatment for a very serious condition,” says Professor Helleday. “We’ll now be developing our OGG1 inhibitor and examining whether it can lead to new treatments for inflammatory diseases in order to cure or relieve diseases such as sepsis, COPD and severe asthma.”
The discovery was made in collaboration with Professor Istvan Boldogh from the University of Texas Medical Branch, USA.
The repair pathway on which OGG1 operates was discovered by Tomas Lindahl at Karolinska Institutet in the 1970s, an achievement that earned him the Nobel Prize in Chemistry in 2015.
Collaboration between several universities
The study was a collaboration between Karolinska Institutet, Uppsala University and Stockholm University in Sweden and the University of Texas Medical Branch, USA.
Learn more: New inflammation inhibitor discovered
The Latest on: Anti-inflammatory drug
[google_news title=”” keyword=”anti-inflammatory drug” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Anti-inflammatory drug
- Anti-Inflammatory Use May Reduce PD Risk in Patients With Autoimmune Diseaseson April 26, 2024 at 6:33 am
Researchers examined the relationship between exposure to anti-inflammatory therapy and the incidence of Parkinson disease in patients with autoimmune conditions.
- AbbVie Lifts 2024 Forecast as Newer Drugs Plug Humira Losseson April 26, 2024 at 4:36 am
AbbVie Inc. lifted its full-year profit guidance as newer anti-inflammatory treatments like Rinvoq and Skyrizi take over for Humira, the blockbuster arthritis drug that fueled the company’s growth for ...
- AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in studyon April 25, 2024 at 7:26 am
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to ...
- Anti-aging biopharma company raises $40 million to begin human testson April 24, 2024 at 5:00 pm
California-based biopharmaceutical company Rubedo Life Sciences has announced that thanks to US$40 million in financial backing, it can commence human trials of its drug RLS-1469, designed to target ...
- Existing drugs studied in patients with rare immune diseaseson April 24, 2024 at 5:48 am
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...
- To Further Impede the Progression of Heart Disease, We Must Treat Patients With Anti-Inflammatory Drugs in Combination With Statin Therapyon April 23, 2024 at 5:00 pm
The good news is that last year the U.S. Food and Drug Administration (FDA)-approved the first anti-inflammatory therapeutic option known as LODOCO ® (colchicine, 0.5 mg) to reduce cardiac event ...
- Investigating the efficacy and safety of existing drugs in patients with rare immune diseaseson April 23, 2024 at 12:26 pm
This month the first study within the DRIMID consortium (DRIMID stands for Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases) has started.
- Cheap, decades-old drug could be secret to longevity: scientistson April 22, 2024 at 9:42 am
A cheap drug used to treat diabetes may help you live a longer, healthier life, scientists believe. Metformin, which helps people lower their blood sugar and treats Type 2 diabetes, could also protect ...
- A cheap drug may slow down aging. A study will determine if it workson April 22, 2024 at 6:02 am
Studies suggest people who take metformin for diabetes may be at lower risk for cancer, heart disease and dementia. Now researchers aim to test if it prevents age-related diseases in healthy people.
via Bing News